Performance of SAGE Sage Therapeutic | -68.3% in 12m
Compare SAGE with Indices, Sectors and Commodities ✔ like Oil, Gas, Gold, Yields and Bonds. Who outperforms?
Compare Sage Therapeutic with its related Sector/Index XBI
Performance Duell SAGE vs XBI
| TimeFrame | SAGE | XBI |
|---|---|---|
| 1 Day | 4.97% | 1.96% |
| 1 Week | -10.6% | 3.53% |
| 1 Month | 1.38% | 8.49% |
| 3 Months | -19.7% | 22.97% |
| 6 Months | -58.3% | 14.24% |
| 12 Months | -68.3% | 20.66% |
| YTD | -51.1% | 12.05% |
| Rel. Perf. 1m | -0.82 | |
| Rel. Perf. 3m | -6.73 | |
| Rel. Perf. 6m | -9.91 | |
| Rel. Perf. 12m | -9.91 |
Is Sage Therapeutic a good stock to buy?
No, based on ValueRay Fundamental Analyses, Sage Therapeutic (NASDAQ:SAGE) is currently (July 2024)
a stock to sell. It has a ValueRay Fundamental Rating of -52.82 and therefor a negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of SAGE as of July 2024 is 7.06. This means that SAGE is currently overvalued and has a potential downside of -32.57% (Sold with Premium).
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of SAGE as of July 2024 is 7.06. This means that SAGE is currently overvalued and has a potential downside of -32.57% (Sold with Premium).
Is SAGE a buy, sell or hold?
- Strong Buy: 1
- Buy: 3
- Hold: 16
- Sell: 1
- Strong Sell: 1
Values above 0%: SAGE is performing better - Values below 0%: SAGE is underperforming
Compare SAGE with Broad Market Indices
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| US S&P 500 | SPY | -9.75% | 1.58% | -70.72% | -88.90% |
| US NASDAQ 100 | QQQ | -8.00% | 5.00% | -67.87% | -89.81% |
| US Dow Jones Industrial 30 | DIA | -11.33% | -2.43% | -65.77% | -84.58% |
| German DAX 40 | DBXD | -10.23% | 0.69% | -66.04% | -82.81% |
| UK FTSE 100 | ISFU | -9.65% | 0.43% | -70.51% | -80.22% |
| Shanghai Shenzhen CSI 300 | CSI 300 | -7.58% | 1.68% | -60.43% | -52.72% |
| Hongkong Hang Seng | HSI | -9.16% | 2.16% | -54.31% | -48.30% |
| Japan Nikkei 225 | EXX7 | -8.00% | 2.58% | -58.95% | -79.62% |
| India NIFTY 50 | INDA | -11.72% | -1.52% | -73.82% | -95.25% |
| Brasil Bovespa | EWZ | -9.65% | -0.01% | -44.18% | -55.91% |
SAGE Sage Therapeutic vs. Sectors
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Communication Services | XLC | -6.68% | 5.79% | -64.99% | -88.95% |
| Consumer Discretionary | XLY | -5.88% | 1.45% | -64.44% | -73.67% |
| Consumer Staples | XLP | -9.75% | 1.01% | -67.42% | -73.44% |
| Energy | XLE | -8.98% | 0.93% | -69.98% | -78.94% |
| Financial | XLF | -9.31% | -2.16% | -70.15% | -91.82% |
| Health Care | XLV | -11.94% | -0.32% | -66.81% | -80.40% |
| Industrial | XLI | -9.48% | -0.39% | -68.33% | -82.86% |
| Materials | XLB | -9.41% | 0.02% | -68.17% | -75.83% |
| Real Estate | XLRE | -9.35% | -4.57% | -63.70% | -77.85% |
| Technology | XLK | -5.76% | 7.09% | -63.31% | -89.27% |
| Utilities | XLU | -11.19% | -0.65% | -75.69% | -77.04% |
| Aerospace & Defense | XAR | -12.24% | -3.79% | -72.66% | -89.17% |
| Biotech | XBI | -14.11% | -7.11% | -72.55% | -88.97% |
| Homebuilder | XHB | -11.09% | -10.66% | -78.13% | -103.23% |
| Retail | XRT | -9.51% | 1.06% | -67.82% | -82.55% |
Does Sage Therapeutic outperform its market, is SAGE a Sector Leader?
No, over the last 12 months Sage Therapeutic (SAGE) made -68.31%, while its related Sector, the SPDR S&P Biotech (XBI) made 20.66%.
Over the last 3 months SAGE made -19.72%, while XBI made 22.97%.
No, over the last 12 months Sage Therapeutic (SAGE) made -68.31%, while its related Sector, the SPDR S&P Biotech (XBI) made 20.66%.
Over the last 3 months SAGE made -19.72%, while XBI made 22.97%.
| Period | SAGE | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | 1.38% | 8.49% | -0.20% |
| 3 Months | -19.72% | 22.97% | 7.46% |
| 12 Months | -68.31% | 20.66% | 20.59% |